pacritinib

This page shows the latest pacritinib news and features for those working in and with pharma, biotech and healthcare.

CTI slumps as Servier-partnered lymphoma drug fails

Thankfully for CTI, it’s been making progress on main pipeline candidate pacritinib, an orally-active kinase inhibitor that targets JAK2, FLT3, IRAK1 and CSF1R and is in phase III testing ... Pacritinib has had its own share of problems, however,

Latest news

Baxalta and CTI complete filing for Jakafi rival in US

Baxalta and CTI complete filing for Jakafi rival in US. Myelofibrosis candidate pacritinib aiming for accelerated approval. ... Baxalta's former parent company Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m.
Baxter and CTI's Jakafi rival clears phase III trial

Baxter and CTI's Jakafi rival clears phase III trial. Myelofibrosis candidate pacritinib moves closer to market. ... Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m deal.
Jakafi cleared for bone marrow disorder by FDA

pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.
Baxter licenses cancer drug from CTI in $172m deal

Baxter licenses cancer drug from CTI in $172m deal. Pacritinib is being investigated to treat blood disorder myelofibrosis. ... he added, noting that additional data on pacritinib will be presented at the American Society of Haematology (ASH) conference
Sanofi pulls development of blood cancer drug

Therapeutics/Baxter's pacritinib.

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Pharma deals in August 2015

Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib.
Deal Watch table for November 2013

232. Cell Therapeutics / Baxter. Licence. JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase.
Pharma deals during November 2013

Cell Therapeutics' experimental JAK2/FLT3 inhibitor, pacritinib. ... Pacritinib, an oral therapy, is currently in phase III development for patients with myelofibrosis and has activity against genetic mutations linked to myelofibrosis, leukaemia and

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Account Director: Excellent benefits

Production Manager – Healthcare Communications: DOE

Senior Systematic Review Analyst - Oxford: Negotiable

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Senior Account Director development role to Business Director, H...: Excellent package

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Account Director: £48, 000 - £60, 000

Events Manager – Med Comms – Surrey: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Medical/ Scientific Director: Salary TBC

Project / Account Manager (Medical Education): Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Scientific Director / Editorial Team Leader: Great salary and benefits

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

New Business Director - PR: Competitive Salary and benefits

Senior Medical Writer (Remote Working): Competitive Salary Offered

Senior Medical Writer: Competitive Salary

Associate Director: £75, 000-90, 000

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Consultant Health Economics - London / Oxford: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...